Rectal Cancer Stage III Clinical Trial
Official title:
Application of MRI Quantitative Parameters in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression group and normal group. The differences of magnetic resonance parameters between the groups were compared. The risk identification model of acute and chronic myelosuppression after neoadjuvant chemoradiotherapy was established by clinical risk factors and quantitative parameters of magnetic resonance imaging, and the prediction efficiency of the model was evaluated.
The patients with locally advanced rectal cancer diagnosed in Peking University Third Hospital and undergoing neoadjuvant chemoradiotherapy were collected. The basic information of patients (including age, sex, BMI, TNM stage of rectal cancer (T2, T3 stage)) was collected. The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy. MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed, and the corresponding parameters were obtained. The white blood cell values and quantitative parameters of magnetic resonance (including T1WI, DWI signal intensity (b = 1000) and proton density fat fraction (PDFF) of sacrilium and proximal femur were collected. Patients were divided into acute myelosuppression group and non-acute myelosuppression group according to blood routine results 14 days after radiotherapy, and chronic myelosuppression group and non-chronic myelosuppression group according to blood routine results 90 days after radiotherapy. The magnetic resonance parameters difference between 1-2 weeks after radiotherapy and before radiotherapy, and the magnetic resonance parameters difference between 90 days after radiotherapy and before radiotherapy were calculated. By comparing the differences of clinical risk factors and quantitative parameters of MRI between the two groups, the meaningful variables were screened out, and the risk identification model of acute and chronic myelosuppression was established. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05495308 -
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
|
||
| Recruiting |
NCT04598984 -
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
|
||
| Active, not recruiting |
NCT04246684 -
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
|
Phase 3 | |
| Completed |
NCT05723965 -
Using Artificial Intelligence to Predict Rectal Cancer Outcomes
|
||
| Not yet recruiting |
NCT05830890 -
Sentinel Lymph Node Biopsy in Rectal Cancer
|
N/A | |
| Recruiting |
NCT04503694 -
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
|
Phase 2 | |
| Completed |
NCT02363374 -
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT03561142 -
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
|
Phase 2 | |
| Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05148767 -
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
|
Phase 4 | |
| Recruiting |
NCT06254521 -
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
|
Phase 2 | |
| Completed |
NCT01325649 -
Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma
|
N/A | |
| Active, not recruiting |
NCT03840239 -
TNT to Increase the Clinical Complete Response Rate for Distal LARC
|
Phase 2 | |
| Active, not recruiting |
NCT03391843 -
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
|
Phase 2 |